Novel Substances in the Treatment of Lung Cancer for the Radiation Oncologist

  • L. Chinsoo Cho
  • Hak Choy
Part of the Medical Radiology Radiation Oncology book series (MEDRAD)


Epidermal Growth Factor Receptor Chemotherapeutic Drug Radiat Oncol Biol Phys Radiation Therapy Oncology Group Concurrent Chemoradiotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akimoto T, Hunter NR, Buchmiller L, et al. (1999) Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5:2884–2890PubMedGoogle Scholar
  2. Amorino GP, Hercules SK, Mohr PJ, et al. (2000) Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-Nitro-20(S)-Camptothecin) as a radiation enhancer. Int J Radiat Oncol Biol Phys 47:503–509CrossRefPubMedGoogle Scholar
  3. Andoh T, Ishii K, Suzuki Y, et al. (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A 84:5565–5569PubMedGoogle Scholar
  4. Bernhard EJ et al. (1998) Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 58:1754–1761PubMedGoogle Scholar
  5. Bernhard EJ et al. (2000) Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 60:6597–6600PubMedGoogle Scholar
  6. Brizel DM et al. (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941PubMedGoogle Scholar
  7. Brizel D, Wasserman TH, Strnad V, et al. (1999) Final report of a phase III randomized trial of amifostine as a radioprotectant in head and neck cancer. Int J Radiat Oncol Biol Phys 45(suppl 3):147–148CrossRefPubMedGoogle Scholar
  8. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58:1408–16PubMedGoogle Scholar
  9. Bush RS et al. (1978) Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 37:302Google Scholar
  10. Cancer and Leukemia Group B. Phase II study of paclitaxel, carboplatin, and gefitinib followed by radiotherapy with or without paclitaxel and carboplatin followed by gefitinib in patients with stage III non-small cell lung cancer — CALGB-30106Google Scholar
  11. Canney PA, Dean S. (1990) Transforming growth factor beta: A promoter of late connective tissue injury following radiotherapy? Br J Radiol 63:620–623PubMedGoogle Scholar
  12. Chen AY, Okunieff P, Pommier Y, et al. (1997) Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res 57:1529–1536PubMedGoogle Scholar
  13. Choy H, et al. (1993) Investigation of taxol as potential radiation sensitizer. Cancer 71:3774–3778PubMedGoogle Scholar
  14. Choy H, MacRae R (2001) Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer. Oncology (Huntingt) 15(1 supply 1):31–36Google Scholar
  15. Cohen-Jonathan E et al (2001) The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 61:2289–2293PubMedGoogle Scholar
  16. Dickstein BN, Wosikowski K, Bates S (1995) Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol Cell Endocrinol 110:205–211CrossRefPubMedGoogle Scholar
  17. Dische S (1988) Modifying radiosensitivity to improve clinical radiotherapy. In: Progress in radio-oncology, IV. International Club of Radio-Oncology, ViennaGoogle Scholar
  18. Eastern Cooperative Oncology Group (ECOG). Phase III randomized study of carboplatin, paclitaxel, and chemoradiotherapy with or without thalidomide in patients with stage III non-small cell lung cancer. Scholar
  19. Eliopoulos AG, Kerr DJ, Herod J, et al. (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 11:1217–1228PubMedGoogle Scholar
  20. Elkind MM, Sutton HF (1959) X-ray damage and recovery in mammalian cells in culture. Nature 184:1293PubMedGoogle Scholar
  21. Faivre S, Le Chevalier T, Monnerat C, et al. (2002) Phase I/II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 13:1479–1489PubMedGoogle Scholar
  22. Fisher BJ, Scott C, Macdonald DR, et al. (2001) Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507. J Clin Oncol 19:1111–1117PubMedGoogle Scholar
  23. Gorski DH, Beckett MA, Jaskowiak NT, et al. (1999) Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374–3378PubMedGoogle Scholar
  24. Grabenbauer GG, Buchfelder M, Schrell U et al. (1999) Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma. Front Radiat Ther Oncol 33:364–368PubMedGoogle Scholar
  25. Gregoire V et al. (1999) Chemo-radiotherapy: radiosensitizing nucleoside analogues. Oncol Rep 6:949–957PubMedGoogle Scholar
  26. Grunicke HH, Maly K (1993) Role of GTPases and GTPase regulatory proteins in oncogenesis. Crit Rev Oncog 4:389–402PubMedGoogle Scholar
  27. Hahn SM et al. (1994) Potential use of nitroxides in radiation oncology. Cancer Res 54(suppl 7):2006s–2010sPubMedGoogle Scholar
  28. Hak Choy, A Nabid, B Stea, W Roa, et al. (2001) Positive phase II results of RSR13 and concurrent radiation therapy after induction chemotherapy with paclitaxel and carboplatin for locally advanced inoperable non-small cell lung cancer. ASCO annual meeting, abstract#1248Google Scholar
  29. Harari PM, Huang SM (2000) Modulation of molecular targets to enhance radiation. ClinCancer Res 6:323–325Google Scholar
  30. Hartford AC, Gohongi T, Fukumura D, et al. (2000) Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: Potential role of host-tumor interaction. Cancer Res 60:2128–2131PubMedGoogle Scholar
  31. Henk JM, Smith CW (1977) Radiotherapy and hyperbaric oxygen in head and neck cancer. Lancet 2:104–105CrossRefPubMedGoogle Scholar
  32. Hermens AF, Barendsen GW (1978) The proliferative status and clonogenic capacity of tumour cells in a transplantable rhabdomyosarcoma of the rat before and after irradiation with 800 rad of X-rays. Cell Tissue Kinet 11:83–100PubMedGoogle Scholar
  33. Hockel M et al. (1993) Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26:45CrossRefPubMedGoogle Scholar
  34. Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722–1726PubMedGoogle Scholar
  35. Hsiang YH, Hertzberg R, Hecht S, et al. (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873–14878PubMedGoogle Scholar
  36. Huang SM, Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166–2174PubMedGoogle Scholar
  37. Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935–1940PubMedGoogle Scholar
  38. Huang SM, Li J, Armstrong EA, et al. (2002) Modulation of radiation response and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD 1839 (Iressa). Cancer Res 62:4300–4306PubMedGoogle Scholar
  39. Iliakis G (1988) Radiation-induced potentially lethal damage: DNA lesions susceptible to fixation. Int J Radiat Biol Relat Stud Phys Chem Med 53:541–584PubMedGoogle Scholar
  40. Kakolyris S, Kouroussis C, Koukourakis M, et al. (2002) A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors. Oncology 63:213–218CrossRefPubMedGoogle Scholar
  41. Kinsella TJ et al. (1987) Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys 13:733–739PubMedGoogle Scholar
  42. Kirichenko AV, Rich TA (1999) Radiation enhancement by 9-aminocamptothecin: the effect of fractionation and timing of administration. Int J Radiat Oncol Biol Phys 44:659–664CrossRefPubMedGoogle Scholar
  43. Kishi K, Petersen S, Petersen C, et al. (2000) Preferential enhancement of tumor radioresponse by a cylooxygenase-2 inhibitor. Cancer Res 60:1326–1331PubMedGoogle Scholar
  44. Koki A, Leahy KM, Masferrer JL (1999) Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Invest Drugs 8:1623–1638CrossRefGoogle Scholar
  45. Komaki R, Seiferheld W, Curran W, et al. (2000) Sequential vs. concurrent chemotherapy and radiation therapy for inoperable phase III study (RTOG 9410). Int J Radiat Oncol Biol Phys 48:113CrossRefGoogle Scholar
  46. Kourousis C, Agelaki S, Mavroudis D, et al. (2003) A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Anticancer Res 23:785PubMedGoogle Scholar
  47. Kuss B, Cotter F (1997) Antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349:1137–1141CrossRefPubMedGoogle Scholar
  48. Lawrence TS, Eisbruch A, Shewach DS (1997) Gemcitabine-mediated radiosensitization. Semin Oncol 24: S-7,24–S7,28Google Scholar
  49. Li C et al. (2000a) Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res 6:2829–2834PubMedGoogle Scholar
  50. Li C et al. (2000b) Potentiation of ovarian OCa-1 tumor radioresponse by poly(L-glutamic acid)-paclitaxel conjugate. Int J Radiat Oncol Biol Phys 48:1119–1126CrossRefPubMedGoogle Scholar
  51. Little JB, et al. (1973) Repair of potentially lethal radiation damage in vitro and in vivo. Radiology 106:689PubMedGoogle Scholar
  52. Maeda H, Seymour LW, Miyamoto Y (1992) Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem 3:351–362CrossRefPubMedGoogle Scholar
  53. Mason KA et al. (2001) Biology-based combined-modality radiotherapy: workshop report. Int J Radiat Oncol Biol Phys 50: 1079–1089CrossRefPubMedGoogle Scholar
  54. Mauceri H.J et al. (1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394:287–291PubMedGoogle Scholar
  55. MD Anderson Cancer Center. Phase III randomized study of induction platinum-based chemotherapy and radiotherapy with or without Æ-941 (Neovastat) in patients with unresectable stage IIIA or IIIB non-small cell lung cancer. Scholar
  56. Mendelsohn J, Fan Z (1997) Epidermal growth factor receptor family and chemosensitization. J Ntl Cancer Inst 89:341–343CrossRefGoogle Scholar
  57. Milas L (2001) Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 11:296–299CrossRefGoogle Scholar
  58. Milas L, Hanson WR (1995) Eicosanoids and radiation. Eur J Cancer 31A:1580–1585CrossRefPubMedGoogle Scholar
  59. Milas L, et al. (1994) Dynamics of tumor cell clonogen repopulation in a murine sarcoma treated with cyclophosphamide. Radiother Oncol 30:247–253CrossRefPubMedGoogle Scholar
  60. Milas L, et al. (1995) Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 55:3564–3568PubMedGoogle Scholar
  61. Milas L, et al. (1999a) Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 59:107–114PubMedGoogle Scholar
  62. Milas L, Milas MM, Mason KA (1999b) Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 9:12–26PubMedGoogle Scholar
  63. Milas L, et al. (1999c) Enhancement of tumor response to gradiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 91:1501–1504CrossRefPubMedGoogle Scholar
  64. Milas L, et al. (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701–708PubMedGoogle Scholar
  65. Moertel CG, Schutt AJ, Reitemeier RJ, et al. (1972) Phase II study of camptothecin SC100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95–101.PubMedGoogle Scholar
  66. Monnet I, Brienza S, Hugret F, et al (1998) Phase II study of oxaliplatin in poor prognosis non-small cell lung cancer (NSCLC). Eur J Cancer 34:1124–1127CrossRefPubMedGoogle Scholar
  67. Monnet I, Soulié P, de Cremoux H, et al. (2001) Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 19:458–463PubMedGoogle Scholar
  68. Monnet I, de Cremoux H, Soulie' P, et al. (2002) Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Ann Oncol 13:103–107CrossRefPubMedGoogle Scholar
  69. Morris M, et al. (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. New Engl J Med 340:1137–1143CrossRefPubMedGoogle Scholar
  70. Muggia FM, Creaven PJ, Hansen HH, et al. (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56:515–521PubMedGoogle Scholar
  71. Munro AJ (1995) An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 71:83–91PubMedGoogle Scholar
  72. Ning S, Laird D, Cherrington JM, et al. (2002) The antiangiogenic agents SU 5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157:45–51PubMedGoogle Scholar
  73. Nordsmark M, Overgard M, Overgard J (1996) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41:31PubMedGoogle Scholar
  74. Omura M, Torigoe S, Kubota N (1997) SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids. Radiat Oncol 43:197–201CrossRefGoogle Scholar
  75. O'Reilly MS et al. (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689–692CrossRefPubMedGoogle Scholar
  76. Phase III randomized study of polyglutamate paclitaxel (CT-2103) versus docetaxel as second-line therapy in patients with progressive non-small cell lung cancer. Scholar
  77. Plunkett W et al. (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22(suppl 11):3–10Google Scholar
  78. Raben D, Helfrich BA, Chan D, et al. (2002) ZD 1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone, and in combination with radiation and chemotherapy as new therapeutic strategy in non-small cell lung cancer. Semin Oncol 29(suppl 4):37–46CrossRefPubMedGoogle Scholar
  79. Radford IR (1986) Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells. Int J Radiat Biol Relat Stud Phys Chem Med 49:611–620PubMedGoogle Scholar
  80. Radiation Therapy Oncology Group. RTOG-0213. Phase I/II study of celecoxib and limited-field radiotherapy in intermediate-prognosis patients with locally advanced non-small cell lung cancer. Scholar
  81. Rafi MM, Rosen RT, Vassil A, et al. (2000) Modulation of Bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res 20:2653–2658PubMedGoogle Scholar
  82. Robert F, Ezekiel MP, Spencer SA, et al. (2001) Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19:3234–3243PubMedGoogle Scholar
  83. Salek MN, Raisch KP, Strackhouse MA, et al. (1999) Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biothera Radiopharm 14:451–463Google Scholar
  84. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al. (1997) Radiation-induced proliferation of the human A431 squamous carcinoma cells dependent on EGFR tyrosine phosphorylation. Oncogene 15:1191–1197CrossRefPubMedGoogle Scholar
  85. Schmidt-Ullrich RK, et al. (2000) Signal transduction and cellular radiation responses. Radiat Res 153:245–257PubMedGoogle Scholar
  86. Solomon B, Hagekyriakou M, Trivett M, et al. (2002) Potentiation of the antitumor effect of ionizinf radiation by ZD 1839 ('Iressa') in vitro and in vivo A431 cells. Proc Am Assoc Cancer Res 43:1002, (abstr 4966)Google Scholar
  87. Southwest Oncology Group. Phase III randomized study of cisplatin, etoposide, radiotherapy, and docetaxel with or without gefitinib in patients with unresectable stage iii non-small cell lung cancer. a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. Also called ZD 1839. SWOG-S0023Google Scholar
  88. Steel GG, Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5:85–91PubMedGoogle Scholar
  89. Stephens T, Steel GG (1980) Regeneration of tumors after cytotoxic treatment. In: Meyn R, Withers HR (eds.) Radiation biology in cancer research. Raven Press, New York, pp 385–295Google Scholar
  90. Takeda K, Negoro S, Kudoh S, et al. (1999) Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer 79:1462–1467CrossRefPubMedGoogle Scholar
  91. Tannock IF, Rotin D (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49:4373–4384PubMedGoogle Scholar
  92. Taylor J, Withers HR, Mendenhall WM (1990) Dose-time considerations of head and neck squamous cell carcinomas treated with irradiation. Radiother Oncol 17:95–102CrossRefPubMedGoogle Scholar
  93. Teicher BA et al. (1995) Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 36:227–236CrossRefPubMedGoogle Scholar
  94. Terasima T, Tolmach.J (1963) Variations in survival responses of HeLa cells to x-irradiation during the division cycle. Biophys J 3:11–33PubMedGoogle Scholar
  95. Tishler RB, et al. (1992) Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52:3495–3497PubMedGoogle Scholar
  96. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449–6465PubMedGoogle Scholar
  97. Vittorio F, Roberto B, Enrico A, et al. (2003) Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. Lung Cancer 41:101–106CrossRefPubMedGoogle Scholar
  98. Wang Y, Pantelias GE, Iliakis G (1994) Mechanism of radiosensitization by halogenated pyrimidines: the contribution of excess DNA and chromosome damage in BrdU radiosensitization may be minimal in plateau-phase cells. Int I Radiat Biol 66: 133–142Google Scholar
  99. Withers HR, Taylor JM, Maciejewski B (1988) The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 27:131–146PubMedGoogle Scholar
  100. Yuhas JM, Storer JB (1969) Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 42:331–335PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • L. Chinsoo Cho
    • 1
  • Hak Choy
    • 1
  1. 1.Department of Radiation OncologyUniversity of Texas, Southwestern Medical Center at DallasDallasUSA

Personalised recommendations